Validation of a deep learning–based AI system for HER2-targeted breast cancer assessment using ultrasound imaging in a clinical setting

These findings highlight the potential of AI-based imaging tools to support real-time treatment monitoring in breast cancer. The observed trend favoring Herceptin suggests that AI-generated risk scores may serve as non-invasive indicators of treatment efficacy. Broader validation across larger, more diverse cohorts is warranted to confirm these preliminary results and further develop AI-guided oncology workflows.